Free Trial
→ Trump’s treachery (From Porter & Company) (Ad)
NASDAQ:MNOV

MediciNova 2/15/2024 Earnings Report

MediciNova logo
$1.41 +0.02 (+1.44%)
Closing price 06/2/2025 03:59 PM Eastern
Extended Trading
$1.42 +0.01 (+0.35%)
As of 06/2/2025 06:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
ProfileEarnings HistoryForecast

MediciNova EPS Results

Actual EPS
-$0.04
Consensus EPS
-$0.08
Beat/Miss
Beat by +$0.04
One Year Ago EPS
N/A

MediciNova Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

MediciNova Announcement Details

Quarter
Date
2/15/2024
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

MediciNova's next earnings date is estimated for Thursday, August 14, 2025, based on past reporting schedules.

Conference Call Resources

MediciNova Earnings Headlines

MediciNova To Participate in D. Boral's Capital Global Conference on May 14, 2025
April 14, 2025 | globenewswire.com
MediciNova says first patient enrolled in EAP trial to evaluate MN-166
April 9, 2025 | markets.businessinsider.com
The Social Security Changes No One’s Talking About
While most Americans worry about their next Social Security check... something far bigger is happening behind the scenes. An AI plan — authorized by Executive Order — is about to rewrite how the SSA operates.
June 3, 2025 | Altimetry (Ad)
First Patient Enrolled in NIH-Funded Expanded Access Program (EAP) Trial to Evaluate MN-166 in Amyotrophic Lateral Sclerosis (ALS) Patients
April 8, 2025 | globenewswire.com
MNOV: Encouraging Interim Analysis for Phase 2b/3 ALS Trial…
December 9, 2024 | msn.com
MediciNova Presents Study Update and Interim Analysis of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS (COMBAT-ALS Clinical Trial) at the 35th International Symposium on ALS/MND
December 5, 2024 | globenewswire.com
See More MediciNova Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like MediciNova? Sign up for Earnings360's daily newsletter to receive timely earnings updates on MediciNova and other key companies, straight to your email.

About MediciNova

MediciNova (NASDAQ:MNOV), a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic fatty liver disease and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has license agreements with Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals, Ltd.; and Meiji Seika Kaisha, Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.

View MediciNova Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles